Articles tagged with Ebola Virus
A new study found that Ebola vaccines provide durable immune responses at one year after vaccination, with 100% of recipients retaining Ebola virus glycoprotein-specific antibodies. The heterologous primary and booster vaccination schedule showed long-lasting immunity, exceeding eight months after primary immunization.
A Phase 1 clinical trial found that a two-vaccine regimen against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers. The investigational vaccines used harmless viral vectors to deliver proteins of the Ebola virus, prompting an immune response.
A Georgia State University researcher has received a five-year grant to develop a new drug targeting the Ebola virus. The goal is to find compounds that block the growth of Ebola virus by inhibiting its viral machinery.
A new oral Ebola vaccine has shown effectiveness in a chimpanzee trial, offering hope for conserving wild ape populations threatened by diseases like Ebola and anthrax. However, the closure of captive chimpanzee facilities due to changing laws may hinder further research and development.
The Nextstrain software tool has won the first-ever international Open Science Prize for its ability to track genetic mutations during disease outbreaks. The platform makes it easier to share and analyze genetic sequencing data, aiming to speed discoveries and improve human health.
A combination of two cancer drugs has been found to inhibit both dengue and Ebola virus infections in mice, with efficacy also shown against West Nile and Zika viruses. The study identified a molecular mechanism by which the drugs disrupt RNA viruses' genetic material.
Researchers at the University of Kent have found that Ebolaviruses require fewer than five mutations to adapt to new host species, including rodents. This finding highlights the potential for these viruses to spread beyond their natural range and increase the risk to humans.
A new study found that Ebola superspreaders were responsible for infecting 61% of all cases in the 2014-15 outbreak. These superspreaders often fit into certain age groups and continue to spread disease after being placed in care facilities.
A Queensland-led team has developed an effective and economical Ebola treatment made with antibodies from horses, which could be used in the next outbreak. The post-exposure treatment is a cost-effective alternative to monoclonal antibodies, which require significant investment for scale-up and manufacture.
Researchers developed a new scale to predict patient outcomes, finding that malaria co-infection, age extremes, and delayed healthcare seeking behavior are key predictors of mortality. The scoring system achieved high accuracy rates of 91% at triage and 97% after triage.
A team of experts reviewed post-Ebola reports to identify key problems and recommendations for reform. They found significant gaps between proposed changes and actual action, particularly in strengthening compliance with International Health Regulations.
Scientists have identified a 'molecular barcode' in blood samples from Ebola patients that can predict survival or death. The analysis provides data on the underlying causes of Ebola virus infection and suggests a potential diagnostic tool to guide treatment strategies.
Researchers used social media and internet reports to analyze exposure patterns during the 2014-2015 Ebola epidemic and 2015 Middle East Respiratory Syndrome outbreak. The study found that alternative data streams can provide reliable information on disease dynamics in the early stages of an outbreak.
Researchers used a new mouse model to study how the Ebola virus affects the immune system, focusing on cellular signaling events. They found that macrophages play a critical role in controlling EBOV infection by producing MAVS, which helps limit organ damage and promotes type I interferon production.
A team of scientists has identified a mechanism to counteract Ebola's ability to spread, revealing that host cells sequester viral proteins away from the plasma membrane. This discovery could lead to a novel antiviral strategy against Ebola.
Scientists discovered Ebola virus RNA lingering in the lungs of a recovering patient for about five days after it cleared from blood. The findings support the possibility of active replication in the lungs, raising potential roles for lung infection in the disease's pathogenesis and transmission.
An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, showing no cases among those vaccinated within 10 days. The vaccine's efficacy also led to indirect protection through herd immunity in unvaccinated people, providing weight to early trial results.
Researchers propose new approaches to fight diseases using economic epidemiological modeling and Lagrangian approach, which consider unique factors of social and geographic patches
Researchers analysed viromes in blood samples from patients with Ebola symptoms, finding potential links between co-infected pathogens and worsening clinical outcomes. The study aims to identify new pathogens and improve diagnosis for other VHFs.
Researchers developed algorithms to track Ebola epidemic spread, revealing that most infected individuals stayed within their districts. The study's findings suggest using this method could inform effective control measures for new emerging epidemics.
Researchers at UTMB engineered Ebola virus variants to study the components disabling the human immune system. The study found that IIDs promote replication of viral particles in cells and counteract the activity of immune cells.
Current knowledge on EVD in great apes highlights the link between ape outbreaks and human transmission through bushmeat consumption. Vaccination of wild apes could reduce both human and animal risk but feasibility is questionable due to elusive ape habitats.
A study published in PLOS Neglected Tropical Diseases found that tens of individuals in Sierra Leone showed no signs of Ebola disease but still tested positive for antibodies, suggesting a minority may contract the virus without symptoms. The discovery raises questions about the scope of the 2013-2016 outbreak and potential transmissio...
A Stanford-led study identified 14 individuals in Sierra Leone who had Ebola antibodies but no symptoms, contradicting previous assumptions about the disease's severity. The research suggests that 25% of Ebola infections were minimally symptomatic, and public health efforts may not have been effective in containing the virus.
A new antimalarial compound, pyronaridine, has shown promising activity against the Ebola virus in laboratory tests. The compound, already approved for use in Europe, was identified through a machine learning model and is being tested in vivo to assess its potential as an Ebola treatment.
A new study co-led by TSRI scientists suggests that Ebola virus gained a genetic mutation, GP-A82V, which helps it better target human cells. This mutation emerged early in the epidemic and caused about 90% of infections during the recent outbreak.
Researchers found mutations in Ebola virus that increased its ability to infect human cells, potentially contributing to the outbreak's spread. The mutations did not affect the virus's ability to infect other mammalian species, including fruit bats.
Antibodies from Ebola survivors can strongly neutralize the virus and protect mice from a lethal challenge. The study found these protective antibodies using a new technology called Immune Repertoire Capture°0niversity.
Healthcare workers who cared for Ebola patients in Sierra Leone described relying on training, guidelines, and equipment to manage risks. They also emphasized the importance of being prepared to face highly contagious and deadly diseases, a concern relevant to global health, according to Dr. Asa Hornsten.
A randomized controlled trial found ZMapp to be safe and well-tolerated, with a 40% lower risk of death for those who received the treatment. However, the trial was conducted during a public health emergency and enrolled too few participants to determine definitively whether ZMapp is superior to standard care alone.
A new therapeutic strategy targeting a shared Achilles' heel of all Ebola viruses has shown promising results. Two monoclonal antibodies blocked the invasion of human cells by all five ebolaviruses, and one protected mice exposed to lethal doses of Ebola Zaire.
Scientists have developed a two-pronged antibody that can counteract the unique immune-evasion mechanism of filoviruses like Ebola. The antibody, called a 'Trojan horse' antibody, targets the glycoprotein on the outside of the virus and prevents it from associating with a specific host-cell receptor in the endosome.
Mass drug administration in Liberia reduced malaria incidence, but actual treatment compliance was low due to misconceptions about health interventions. The study found a significant decline in monthly malaria fever cases from 4.3% to 1.5% after the intervention.
Scientists have discovered a new class of small molecule compounds that can block the Ebola virus's ability to break out of cells and infect new ones. The compounds target an interaction between the virus and host cells, inhibiting viral egress without being toxic to human cells.
Scientists at the University of Texas Medical Branch have successfully treated rhesus macaques infected with Sudan ebolavirus using an RNA-based therapeutic called siRNA, administered via a lipid nanoparticle platform. The treatment was effective in preventing replication of the virus and improving survival rates.
Researchers at UTMB have protected nonhuman primates against Ebola Sudan four days after infection using a siRNA-based treatment. The treatment was effective even when animals showed signs of disease and had detectable levels of the virus in their blood.
A study published in Clinical Infectious Diseases found that people infected with Ebola virus were 20% more likely to survive if they were co-infected with malaria-causing Plasmodium parasites. The survival difference was evident even after controlling for Ebola viral load and age.
Researchers at TSRI have developed a high-resolution view of how the ZMapp experimental therapy targets Ebola virus. The study revealed detailed images of the protein structures, providing new clues to improve the effectiveness of the antibodies in the treatment.
A study published in PLOS Medicine found that maternal health services in rural Liberia suffered a significant impact during the Ebola epidemic, with facility-based deliveries decreasing by approximately 8%. The researchers noted that fear of transmission in health facilities was a major factor contributing to this decline.
The Ebola epidemic led to a significant decline in child and maternal health in Liberia, with a 30% reduction in facility-based deliveries. The study found that fear of Ebola transmission in healthcare facilities was the primary factor contributing to this decline.
Researchers have identified a modified human protein essential for Ebola virus replication, offering new targets for therapeutic development.
A team of scientists has developed a model that can predict which bat species are most likely to transmit Ebola and other filoviruses. The study highlights new potential hosts and geographic hotspots worthy of surveillance, with the AI algorithm identifying potential carriers in Southeast Asia and Central and South America.
Ecologists have identified 21 bat species that are likeliest to harbor Ebola and other filoviruses, primarily found in Southeast Asia and Central and South America. The study suggests targeted disease surveillance efforts in these regions to prevent future outbreaks.
Researchers tested serum antibodies from Ebola survivors and found substantial cross-reactivity with other filoviruses, suggesting long-lived immunity. The study's results indicate that antibody responses extend beyond the primary virus, imparting at least partial immunity to other filoviral infections.
The PREVAIL IV trial is a six-month study enrolling 60-120 EVD survivors with evidence of Ebola virus RNA in their semen. Participants will receive either investigational drug GS-5734 or a placebo to see if it can eliminate the viral RNA from semen.
The 1976 Ebola outbreak highlighted the importance of rapid clinical recognition, international notification, and specimen provision. Researchers recommend strengthened preparation, detection, response, control mechanisms, and international cooperation to manage future outbreaks promptly.
New research suggests that sexual transmission of Ebola could have a major impact on the dynamics of the disease. The study found that even small and short outbreaks with sexual transmission were larger and longer-lasting than those without it.
The University of Alabama at Birmingham is developing a training program to equip health care and public safety workers with the skills and knowledge needed to protect themselves and their communities from potential exposure to contaminated materials or infected individuals. The program, funded by the National Institute of Environmenta...
Scientists at the University of Texas at Austin developed a new method to rapidly detect single viruses in urine, including Ebola, Zika, and HIV. The technique is highly selective and can be used with urine straight from a person or animal, unlike other methods that require higher concentrations or purification.
A new PLOS Medicine article highlights the need for strengthened national health systems, consolidated global emergency response activities, and enhanced research and development to prevent and respond to future infectious disease threats. The study's authors emphasize that system-wide accountability and continuous oversight are crucia...
A study published in Virus Evolution found that unconventional transmission routes like semen and breast milk contributed to the tail-end of the Ebola epidemic in Sierra Leone. The research used real-time sequencing of Ebola virus genomes to track the source of infection for some final cases.
The next WHO director general must establish a well-coordinated system for preventing and responding to outbreaks, strengthen accountability mechanisms, and engage private sector foundations during public health emergencies. This is according to experts' analysis of key questions for prospective candidates.
Cardiovascular magnetic resonance (CMR) is a stronger predictor of risk for major adverse cardiovascular events (MACE) than single-photon emission computed tomography (SPECT). CMR has higher sensitivity and negative predictive value compared to SPECT, making it a robust alternative for diagnosing coronary heart disease.
A phase I trial of the rVSV-ZEBOV vaccine in Africa and Europe has shown promising results, with antibodies detectable after six months. The vaccine stimulates a strong immune response and appears to control virus replication.
Genomic analysis of Ebola virus samples from Liberia in June 2015 indicates a re-emergence of a persistently infected source, highlighting the risk of disease flare-ups even after an outbreak is declared over. The study's findings suggest that the virus replicates at a lower rate during persistent infections.
Researchers have discovered a potential treatment for sepsis and other responses to infection by using tiny doses of a cancer drug. The new treatment may benefit millions worldwide who are affected by infections and pandemics.
A handheld instrument has been developed to detect the Ebola virus quickly and efficiently, allowing for faster treatment and real-time monitoring of viral loads. The device can process four samples simultaneously and produces results in under 37 minutes, significantly reducing the testing time required by conventional methods.
An immunization regimen using two Ebola vaccine candidates was found to be safe and well-tolerated, inducing an immune response in healthy adult volunteers. The study's results suggest that the vaccines could provide durable protection against Ebola, which is essential for areas with intermittent outbreaks.
A phase 1 trial evaluated two candidate Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo, in healthy volunteers. The study found that immunization with Ad26.ZEBOV generated an initial immune response and sustained elevation of specific immunity, suggesting partial protection against Ebola.
A clinical trial of the experimental Ebola drug TKM-130803 has shown that it does not improve survival in adults with severe Ebola infection. Despite this, the study suggests that the drug may have a benefit for patients with less severe disease.